The Food and Drug Administration (FDA) declined on Friday to approve MDMA-assisted psychotherapy as a treatment for post-traumatic stress disorder (PTSD). The agency has asked Lykos Therapeutics, ...

But the FDA quashed advocates’ dreams on Aug. 9, saying MDMA cannot be approved based on the data currently available and ...

Add Yahoo as a preferred source to see more of our stories on Google. The research that the FDA considered was spearheaded by the Multidisciplinary Association for Psychedelic Studies (MAPS), which ...

The Food and Drug Administration’s (FDA) recent rejection of midomafetamine (MDMA), along with mental health therapy, for the treatment of post-traumatic stress disorder (PTSD) came as no surprise.

Lykos Therapeutics, the drug’s manufacturer, said the agency requested an additional phase 3 clinical trial to study the drug’s safety and efficacy, according to an Aug. 9 news release from the ...

MDMA-assisted psychotherapy is demonstrating to be promising for PTSD. Source: Activedia/Pixabay, Creative Commons In recent years, MDMA-assisted psychotherapy has been highlighted as a breakthrough ...

We’re honored to welcome Bruce Sewick, LCPC, CADC, a nationally respected educator and clinician, for a powerful presentation on MDMA-assisted psychotherapy and its transformative potential for ...

A decades-long campaign to legalize MDMA as a mainstream medical treatment will reach a climax as soon as Friday, with the Food and Drug Administration poised to decide whether the psychedelic should ...

When the Food and Drug Administration (FDA) declined to approve MDMA-assisted psychotherapy as a treatment for post-traumatic stress disorder (PTSD) last year, the details of its objections were not ...